A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation Read more about A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation
Cholecalciferol supplementation in critically ill patients with severe vitamin D deficiency in intensive care unit – a randomized controlled trial Read more about Cholecalciferol supplementation in critically ill patients with severe vitamin D deficiency in intensive care unit – a randomized controlled trial
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation Read more about A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma Read more about A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis Read more about A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease Read more about A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease
International, randomized, open label study to compare the safety and efficacy of lixisenatide vs sulfonylurea on top of basal insulin treatment in Type 2 Diabetes Mellitus subjects who elect to fast during Ramadan Read more about International, randomized, open label study to compare the safety and efficacy of lixisenatide vs sulfonylurea on top of basal insulin treatment in Type 2 Diabetes Mellitus subjects who elect to fast during Ramadan
Multicenter Inetrnational neoadjuvant randomized double-blind trial comparing fulvestrant to a combination of fulvestrant and palcociclib in patients with operable luminal breast cancer responding to fulvestrant Read more about Multicenter Inetrnational neoadjuvant randomized double-blind trial comparing fulvestrant to a combination of fulvestrant and palcociclib in patients with operable luminal breast cancer responding to fulvestrant
"A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition tothe Paliperidone Palmitate 3-Month Formulation in Patients with SchizophreniaPreviously Stabilized on the Paliperidone Palmitate 1-Month Formulation" Read more about "A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition tothe Paliperidone Palmitate 3-Month Formulation in Patients with SchizophreniaPreviously Stabilized on the Paliperidone Palmitate 1-Month Formulation"
"A Randomized controlled Trial of Influenza Vaccineto Reduce Adverse Vascular Events" Read more about "A Randomized controlled Trial of Influenza Vaccineto Reduce Adverse Vascular Events"
